Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Skin and Soft Tissue Infections, Infectious Disease, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Immunology / Infectious Diseases, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/18/2017 |
| Start Date: | June 2013 |
| End Date: | April 2014 |
Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States
This study is a single-site trial assessing the specificity of CL Detect™ Rapid Test versus
the gold standard for Leishmania diagnosis in the US which is microscopic identification of
Leishmania amastigotes in a stained lesion sample. Subjects will be patients who present for
dermatology consultation with a primarily ulcerated lesion. After informed consent is
obtained and the subject is screened for eligibility, 2 diagnostic samples will be collected
from the subject's lesion in the following order: 1) one sample will be obtained with a
dental broach for use with the CL Detect™ Rapid Test and 2) a second sample will be obtained
by scraping for use in the microscopic identification of amastigotes. Samples will be
analyzed by microscopy and CL Detect™ Rapid Test. The CL Detect™ Rapid Test will be performed
by different operators who are clinical staff members. These staff members, blinded to each
other's results, will evaluate the samples from each method independently. Each of the 150
study subjects will be followed administratively to the point where a diagnosis is
established (if possible) for their tested lesion, even if that diagnosis is not cutaneous
leishmaniasis (CL). If a specific diagnosis cannot be determined for a non-CL lesion, the
investigator will assign a "likely etiology" (eg, infectious, oncological, immunological,
vascular, or "undetermined/other" origin). Based on the diagnosis determined for each lesion,
subjects will be referred for appropriate treatment.
the gold standard for Leishmania diagnosis in the US which is microscopic identification of
Leishmania amastigotes in a stained lesion sample. Subjects will be patients who present for
dermatology consultation with a primarily ulcerated lesion. After informed consent is
obtained and the subject is screened for eligibility, 2 diagnostic samples will be collected
from the subject's lesion in the following order: 1) one sample will be obtained with a
dental broach for use with the CL Detect™ Rapid Test and 2) a second sample will be obtained
by scraping for use in the microscopic identification of amastigotes. Samples will be
analyzed by microscopy and CL Detect™ Rapid Test. The CL Detect™ Rapid Test will be performed
by different operators who are clinical staff members. These staff members, blinded to each
other's results, will evaluate the samples from each method independently. Each of the 150
study subjects will be followed administratively to the point where a diagnosis is
established (if possible) for their tested lesion, even if that diagnosis is not cutaneous
leishmaniasis (CL). If a specific diagnosis cannot be determined for a non-CL lesion, the
investigator will assign a "likely etiology" (eg, infectious, oncological, immunological,
vascular, or "undetermined/other" origin). Based on the diagnosis determined for each lesion,
subjects will be referred for appropriate treatment.
Inclusion Criteria:
- At least 18 years of age
- Subject is able to give written informed consent
- Subject has a skin ulcer that satisfies the following criteria for an index lesion:
- less than 4 months in age
- primarily ulcerative, not purely verrucous or nodular, and does not have clear
clinical evidence of cellulitis
- in a location suitable for collecting samples by dental broach and scraping
- In the opinion of the investigator, the subject is capable of understanding and
complying with the protocol
Exclusion Criteria:
- Received treatment for leishmaniasis or any treatment to the lesion even if not
previously diagnosed as leishmaniasis such as azoles, cryotherapy, imiquimod,
thermotherapy, photodynamic therapy, within 2 months prior to signing the consent
form, with the exception of mercurochrome
We found this trial at
1
site
Click here to add this to my saved trials
